FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384927758> ?p ?o ?g. }

• W4384927758 endingPage "247" @default.
• W4384927758 startingPage "236" @default.
• W4384927758 abstract "Background . The therapy of chronic pain in cancer patients is a highly topical issue for the modern health care system. Intense pain syndrome involves the prescription of strong opioid analgesics (ОА), most of which are classified as narcotic drugs and are under strict governmental control. In this situation, increasing the use of drugs that are equivalent in dosages to morphine and do not require a special narcotic drug prescription may increase the availability of pain relief for cancer patients and will be less associated with drug addiction. Objective : to analyze the regulatory, organizational, clinical, and economic criteria that determine the choice and influence the prescription of strong ОА for adequate pain relief in cancer patients with chronic pain syndrome (CPS). Material and methods. The article determines legal and regulatory framework regulating the sphere of providing patients with ОА, presents an expert evaluation of existing barriers that limit the availability of adequate pain treatment, and shows ways to solve these issues. We present the results of an original Russian clinical and economic study evaluating the use of prolonged forms of ОА (tapentadol and morphine) for the treatment of moderate and severe CPS in patients with cancer in the Russian healthcare system. The evidence for comparative clinical efficiency and safety of ОА under consideration is analyzed. The costs of therapy with the drugs in equivalent dosages that provide 1 year of adequate analgesia for intensive CPS in oncology patients are compared. Results . Differences in the regulatory status of opioids, including requirements for prescribing, storage, record keeping, and use, were shown to affect the availability of pain medication. According to a systematic review of the comparative efficiency and safety of prolonged forms of ОА in the therapy of cancer patients with moderate and severe CPS and a meta-analysis of randomized controlled trials, no differences were found for any of the outcomes studied in the tapentadol and morphine groups: frequency of achieving pain control – risk ratio (RR) 0.88 (95% confidence interval (CI) 0.78–1.00), frequency of using emergency (additional) pain relief – RR 1.16 (95% CI 0.95–1.42), frequency of gastrointestinal adverse events – RR 0.82 (95% CI 0.60–1.12). This suggests comparable efficiency and safety of the drugs. The difference in average cost of 1 patient course of therapy for 1 year between tapentadol and morphine was 17,653.02 rubles (–16.8%). Additional funds released in case of treating the cohort of 100 patients with tapentadol instead of morphine made 1,765,301.96 rubles, which means 20 more patients could be treated with tapentadol for 1 year. Conclusion . The use of modern effective non-invasive forms of ОА (tapentadol in particular) that have no restrictions imposed by regulatory documents on narcotic drugs prescription will increase availability, as well as reduce costs of adequate therapy of moderate and severe CPS in patients with cancer as compared to the use of equivalent daily doses of morphine." @default.
• W4384927758 created "2023-07-22" @default.
• W4384927758 creator A5041702387 @default.
• W4384927758 creator A5045574856 @default.
• W4384927758 creator A5089670356 @default.
• W4384927758 date "2023-07-19" @default.
• W4384927758 modified "2023-09-24" @default.
• W4384927758 title "Analysis of social and economic aspects of using prolonged forms of opioid analgesics for the treatment of chronic pain syndrome in cancer patients" @default.
• W4384927758 cites W2015483703 @default.
• W4384927758 cites W3130168933 @default.
• W4384927758 cites W3136840288 @default.
• W4384927758 cites W4200229854 @default.
• W4384927758 cites W4210674904 @default.
• W4384927758 cites W4236776068 @default.
• W4384927758 doi "https://doi.org/10.17749/2070-4909/farmakoekonomika.2023.177" @default.
• W4384927758 hasPublicationYear "2023" @default.
• W4384927758 type Work @default.
• W4384927758 citedByCount "0" @default.
• W4384927758 crossrefType "journal-article" @default.
• W4384927758 hasAuthorship W4384927758A5041702387 @default.
• W4384927758 hasAuthorship W4384927758A5045574856 @default.
• W4384927758 hasAuthorship W4384927758A5089670356 @default.
• W4384927758 hasBestOaLocation W43849277581 @default.
• W4384927758 hasConcept C118552586 @default.
• W4384927758 hasConcept C121608353 @default.
• W4384927758 hasConcept C126322002 @default.
• W4384927758 hasConcept C160735492 @default.
• W4384927758 hasConcept C162156334 @default.
• W4384927758 hasConcept C162324750 @default.
• W4384927758 hasConcept C170493617 @default.
• W4384927758 hasConcept C177713679 @default.
• W4384927758 hasConcept C1862650 @default.
• W4384927758 hasConcept C2426938 @default.
• W4384927758 hasConcept C2775849661 @default.
• W4384927758 hasConcept C2777389121 @default.
• W4384927758 hasConcept C2778904085 @default.
• W4384927758 hasConcept C2780505013 @default.
• W4384927758 hasConcept C2781063702 @default.
• W4384927758 hasConcept C2781118164 @default.
• W4384927758 hasConcept C42219234 @default.
• W4384927758 hasConcept C48856860 @default.
• W4384927758 hasConcept C50522688 @default.
• W4384927758 hasConcept C55932262 @default.
• W4384927758 hasConcept C71924100 @default.
• W4384927758 hasConcept C98274493 @default.
• W4384927758 hasConceptScore W4384927758C118552586 @default.
• W4384927758 hasConceptScore W4384927758C121608353 @default.
• W4384927758 hasConceptScore W4384927758C126322002 @default.
• W4384927758 hasConceptScore W4384927758C160735492 @default.
• W4384927758 hasConceptScore W4384927758C162156334 @default.
• W4384927758 hasConceptScore W4384927758C162324750 @default.
• W4384927758 hasConceptScore W4384927758C170493617 @default.
• W4384927758 hasConceptScore W4384927758C177713679 @default.
• W4384927758 hasConceptScore W4384927758C1862650 @default.
• W4384927758 hasConceptScore W4384927758C2426938 @default.
• W4384927758 hasConceptScore W4384927758C2775849661 @default.
• W4384927758 hasConceptScore W4384927758C2777389121 @default.
• W4384927758 hasConceptScore W4384927758C2778904085 @default.
• W4384927758 hasConceptScore W4384927758C2780505013 @default.
• W4384927758 hasConceptScore W4384927758C2781063702 @default.
• W4384927758 hasConceptScore W4384927758C2781118164 @default.
• W4384927758 hasConceptScore W4384927758C42219234 @default.
• W4384927758 hasConceptScore W4384927758C48856860 @default.
• W4384927758 hasConceptScore W4384927758C50522688 @default.
• W4384927758 hasConceptScore W4384927758C55932262 @default.
• W4384927758 hasConceptScore W4384927758C71924100 @default.
• W4384927758 hasConceptScore W4384927758C98274493 @default.
• W4384927758 hasIssue "2" @default.
• W4384927758 hasLocation W43849277581 @default.
• W4384927758 hasOpenAccess W4384927758 @default.
• W4384927758 hasPrimaryLocation W43849277581 @default.
• W4384927758 hasRelatedWork W1519235934 @default.
• W4384927758 hasRelatedWork W1594452357 @default.
• W4384927758 hasRelatedWork W1910842322 @default.
• W4384927758 hasRelatedWork W2015483703 @default.
• W4384927758 hasRelatedWork W2068519900 @default.
• W4384927758 hasRelatedWork W2138019095 @default.
• W4384927758 hasRelatedWork W4210674904 @default.
• W4384927758 hasRelatedWork W4296795193 @default.
• W4384927758 hasRelatedWork W4311857810 @default.
• W4384927758 hasRelatedWork W643382046 @default.
• W4384927758 hasVolume "16" @default.
• W4384927758 isParatext "false" @default.
• W4384927758 isRetracted "false" @default.
• W4384927758 workType "article" @default.